- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 606183, 10 pages
Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity
1Medical Biology Unit, Medical University of Lublin, 20-059 Lublin, Poland
2Human Anatomy Department, Medical University of Lublin, 20-059 Lublin, Poland
3Histology and Embryology Department, Medical University of Lublin, 20-059 Lublin, Poland
4Department of Pulmonolgy, Oncology and Alergology, Medical University of Lublin, 20-059 Lublin, Poland
5Clinical Pathomorphology Department, Medical University of Lublin, 20-059 Lublin, Poland
6Department of Toxicology, Poznan University of Medical Sciences, 60-780 Poznan, Poland
Received 18 April 2012; Revised 17 October 2012; Accepted 24 October 2012
Academic Editor: R. Govindarajan
Copyright © 2012 Jaroslaw Dudka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The aim of the study was to evaluate the effect of resveratrol in doxorubicin-induced cardiac and hepatic toxicity. Doxorubicin was administered once a week throughout the period of 7 weeks with 1.0 or 2.0 mg/kg body weight or concomitantly with resveratrol (20 mg/kg of feed). Heart and liver toxicity was histologically and biochemically evaluated. Resveratrol protected from the heart lipid peroxidation caused by 1 mg doxorubicin and it sharply diminished superoxide dismutase activity. An insignificant effect of resveratrol on the lipid peroxidation level and the superoxide dismutase activity was observed in the hearts of rats administered a higher dose of doxorubicin. However, resveratrol attenuate necrosis and other cardiac histopathological changes were induced by a high dose of doxorubicin. Interestingly, it slightly intensified adverse cardiac histological changes in rats receiving a lower dose of doxorubicin. Resveratrol did not have any protective effect on the hepatic oxidative stress, while exerting a mild beneficial effect on the morphological changes caused by doxorubicin. All in all, this study has shown different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Resveratrol may modulate the hepatic and cardiac effect of doxorubicin, depending on the drug dose.
Drug-drug and drug-food interactions are specially important in the anticancer therapy because of the very narrow therapeutic index of these chemotherapeutics. Moreover, many patients suffering from cancer in the terminal state decide to take unconventional agent, very frequently beyond of a doctor knowledge.
Doxorubicin (DOX) is a very efficient antitumor drug, but its administration is limited by a dose-dependent, irreversible, and progressive cardiomyopathy, which may become evident years after completion of the therapy [1–5]. The pathomechanism of DOX-related late cardiotoxicity is multifactorial [6, 7], but the prevalent hypothesis ascribes the dominant role to oxidative stress linked to redox-cycling of the drug [8, 9]. The DOX redox-cycling is started from one-electron reduction with the formation of DOX radical (DOX*) . Many NADPH and NADH-dependent enzymes catalyze that reaction, for example, NADPH cytochrome P450 reductase , NOS [11–13], NADPH oxidase [14, 15], and catalase . Subsequently, DOX* are reoxygenated to the nonradical parent compound while at the same time the superoxide anion radical is formed (). This cycle of reactions may repeat many times leading to overproduction of , which is the source of hydrogen peroxide and much more toxic hydroxyl radical [6, 17]. These reactive oxygen species (ROS) are responsible for oxidative stress. The above-mentioned enzymes involved in DOX* production are abundant in hepatocytes , suggesting that liver may be specially involved in DOX* generation. Although no such intense DOX synthase takes place in the heart, relatively low antioxidant defense of cardiomyocytes makes the heart a target for DOX toxicity . The studies of the last decade have been focussed towards the understanding of the latent period of DOX-mediated cardiomyopathy caused by oxidative stress. Redox cycling transformation occurs in cytoplasm, endoplasmatic reticulum, and specially in mitochondria . Oxidative changes in mitochondrial DNA are responsible for disturbances in mitochondrial protein synthesis. For that reason, the product of the electron transfer chain is not only four electron reduced oxygen (H2O) but also ROS—one, two, and three electron products—, H2O2, and HO*, respectively . On the other hand, the oxidation of mtDNA by ROS appears again. In the beginning, the symptoms during that latent period are not clinically overt [22, 23]. Insufficiency of mitochondria function becomes more visible with the pass of time. For that reason, participation of glycolysis pathway in ATP synthesis arises. Eventually, after months or years, the death of cardiomyocytes [24, 25] can consequently lead to heart failure [26, 27].
Resveratrol (3,5,4′-trihydroxystilbene) is a polyphenol, presents in some plants growing in Mediterranean countries (grapes), Minor Asia (hellebore), and Japan (knotweed), is easy achievable as a diet supplement. Resveratrol has been studied in many clinical trials [28, 29] and has shown anticancer [30–32], cardioprotective [33–35], and antioxidant activity [36–39]. Previous studies demonstrated that resveratrol causes resistance to oxidant injury in rats’ neonatal cells (H9c2) , and it prevents from cardiomyocytes’ cytotoxicity of DOX through mitochondrial stabilization .
Thus, resveratrol having antioxidative and anticancer activity can be additionally taken as a supplement by the doxorubicin-treated patient. The aim of this study was to verify the hypothesis according to which resveratrol protects against oxidative injury and pathomorphological changes caused by DOX.
2. Materials and Methods
2.1. Animals and Treatment
The experimental protocol was approved by the Local Bioethical Council of the Medical University in Lublin. The study was conducted on sexually mature male albino rats of Wistar CRL:(WI)WUBR strain, obtained from a commercial breeder (Warszawa-Rembertow, Poland). Animals with the initial body weight of 160–195 g were maintained in stable conditions at 22°C with a 12 h light/dark cycle and given standardized granulated fodder LSM (AGROPOL, Poland). The rats were exposed to doxorubicin (DOX; Ebewe, Austria) and resveratrol (RV, Sigma-Aldrich, USA). The animals were randomly divided into control () and 4 study groups (): 1DOX and 2DOX where doxorubicin was injected intraperitoneally alone in a dose of 1.0 or 2.0 mg/kg body weight, respectively. In groups 1DOX+RV and 2DOX+RV, doxorubicin was administered according to the same scheme concomitantly with resveratrol given with the fodder LSM prepared by AGROPOL in the concentration 20 mg/kg of fodder (20 ppm). In the control group, a 0.9% NaCl was intraperitoneally injected. Doxorubicin was dissolved with saline 1 : 2 v/v and injected once a week for seven weeks in all study groups. Dietary resveratrol supplementation was started one week before the administration of doxorubicin and followed throughout the study. Since in most of previous studies [42, 43] resveratrol in the selected dose (20 mg/kg) did not show any significant effect on hepatic and cardiac morphology and function, secondary to the suggestion of the local Bioethical Committee the group exposed exclusively to resveratrol was not designated. 96 hours after administration of the last dose of doxorubicin, the animals were anesthetized by the intraperitoneal administration of 1 mg/kg pentobarbital, and the blood was collected from the left cardiac ventricle. Immediately after decapitation, the heart and liver samples were collected during autopsy. The organs were washed with saline and then the heart was sectioned along the interventricular and coronal grove. The wall of the left ventricle and the liver samples were placed in liquid nitrogen and stored at −75°C until the time of biochemical analysis. The right ventricular wall and the liver samples were fixed in buffered 10% formalin and routinely histologically processed to paraffin blocks.
2.2. Serum and Plasma Parameters
The concentrations of both rat heart fatty acid binding protein (H-FABP, Life Diagnostic, USA) and rat brain natriuretic peptide (BNP, Phoenix Pharmaceuticals, USA) were determined, respectively, in rat serum and plasma, using ELISA commercial kits. In both cases, two types of antibodies were used in the evaluation: antibodies covering microtiter plate and the secondary antibodies bound to horseradish peroxidase. The products of the catalytic reactions were spectrofotometrically detected at 450 nm.
Serum activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), kreatine kinase CK, lactated dehydrogenase (LDH) and alkaline phosphatase (ALP) was determined using standard kits of CORMAY (Poland).
2.3. Cardiac and Hepatic Oxidative Markers
All measurements were conducted on homogenates obtained from ~20 mg of frozen cardiac or hepatic samples using the extraction buffer provided by the manufacturer of each commercial kit. The evaluation of lipid peroxidation in cardiac and hepatic homogenates was based on malondialdehyde and 4-hydroxyalkenals concentration (MDA+4HAE) using the commercial kit (Bioxytech LPO-586; OxisResearch, USA). The concept of the method is based on the reaction between MDA and 4HAE with N-methyl-2-phenylindol. After mixing N-methyl-2-phenylindole and methanol with the supernatant acquired from the homogenization, methanesulfonic acid was added and all reagents were placed at the temperature of 45°C for 60 minutes. Next, the solution was centrifuged and the supernatant containing the product was transferred to the plastic plate used in the spectrophotometric reader PowerWave XS (BioTek, USA) at 586 nm. Subsequently, the procedure was conducted according to the manufacturer’s description and the concentration of MDA+4HNE in the tested samples was calculated from the formula of the calibration curve y = 0.0896x − 0.008. The obtained date was calculated taking into account the recommendation described in the procedure. The obtained results were expressed in nmol/g cardiac or hepatic sample.
Glutathione determination was conducted using a commercial kit Bioxytech GSH/GSSG-412 (OxisResearch, USA). The frozen cardiac or hepatic samples (~20 mg) were homogenized in the extraction buffer provided by the manufacturer. Total glutathione ( GSH (reduced glutathione) + GSSG (oxidized glutathione)) was determined in the enzymatic reaction, where Ellman’s reagent (5,5′-dithiobis-2-nitrobenzoic acid) reacts with GSH forming a color product with the maximum of absorbance at 412 nm. The concentrations of GSH, GSSG, and GSH/GSSG ratio were assessed after measuring the speed of the reaction and establishing the calibrations curves. The concentrations of GSH and GSSG were determined based on the calibration curve described by the formulae: y = 0.1447x + 0.0004 and y = 0.1475x, respectively. The obtained data was used to calculate the GSH/GSSG ratio.
The activity of superoxide dismutase activity (SOD) was determined colorimetrically using Bioxytech SOD-525 kit (OxisResearch, USA). The method is based on SOD-mediated increase in the rate of autoxidation of 5,6,6 a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]fluorine in alkaline solution to yield chromophore with the maximum of absorbance at 525 nm.
The activity was measured by kinetic spectrophotometric plate reader using a PowerWave XS (BioTek, USA). The mean value in the proper control groups (for cardiac or liver samples) was assumed to be 100%.
2.4. Preparation of Slides for Histological Evaluation
4 μm histological slides obtained from paraffin blocks were routinely processed and stained with hematoxylin and eosin (H&E). To visualize cardiomyocyte necrosis, Selye’s method was also used. Liver slides were also stained with van Gieson, paS (periodic acid-Schiff), and d-paS (diastase + paS).
2.5. Statistical Analysis
The obtained data was expressed as mean ± SD and analyzed by STATISTICA 5.0 software. Continuous data were compared among the experimental groups using the Kolmogorov-Smirnov test. The statistical significance of differences between control and study groups was evaluated by Student’s t-test or Mann-Whitney U test. Group-to-group comparisons were made by one-way ANOVA. A value of was considered as statistically significant.
Lack of animal mortality was found during the study. Food and water consumption, as well as body weight gain, were insignificant between the xenobiotic-exposed and control groups. A significant increase of FABP and BNP levels was observed in rats exposed to the higher dose of doxorubicin (Table 1). Moreover, resveratrol significantly reduced the concentration of both parameters in animals receiving a higher dose of doxorubicin to the levels below of control.
Aspartate aminotransferase (AST) activity was significantly decreased in the group concomitantly exposed to a higher dose of doxorubicin and resveratrol. On the other hand, alanine aminotransferase (ALT) activity was increased in animals exposed to both resveratrol and a low dose of doxorubicin but decreased among the rats treated with resveratrol and a high dose of the drug. A statistically significant decrease of lactate dehydrogenase (LDH) activity was noted in the groups exposed to a high dose of doxorubicin with or without resveratrol. In the case of creatine kinase (CK) activity, an significant change was also revealed in the group treated with resveratrol and a higher dose of the drug. A significant decrease of the ALP activity was found in all the xenobiotic-exposed groups. However, no significant changes in the activity of all the above-mentioned enzymes were noticed between the groups the DOX+RV versus DOX group.
Unlike the insignificant changes of GSHT in cardiac homogenates, all other parameters of oxidative stress were highly affected by the tested substances (Table 2). Significant changes of MDA+4HAE, GSH/GSSG ration, and SOD were found in groups exposed to a high dose of doxorubicin with or without resveratrol. An increase of MDA+4HAE was also noted among the animals exposed exclusively to a low dose of doxorubicin. A decrease of SOD activity was found in the group cotreated with resveratrol and a low dose of the drug as well. The value was also significantly lower when compared to the group exposed only to a low dose of doxorubicin. A similar effect among the groups 1DOX+RV and 1DOX were found in case of MDA+4HAE. Insignificant differences in hepatic GSHT, and SOD level were found in all studied groups comparing to the control. However, the GSH/GSSG ratio was significantly lower in both groups receiving a higher dose of doxorubicin versus control (Table 3), while MDA+4HNE was significantly higher in all tested groups comparing to the control. No significant changes in liver-determined oxidative markers between the DOX+RV versus DOX group were found. Several complex changes in relative values of oxidative stress markers between heart and liver were observed only in the group of RV+1DOX (Figures 1, 2, 3, and 4). These rats had significantly higher relative changes in liver MDA+4HNE, GSHT and SOD level than in the heart. A similar result referring to GSHT was found in 1DOX and referring to the SOD in 2DOX. There were no significant changes between heart and liver in GSH/GSSG relative values in all studied groups.
Histological cardiac abnormalities in the untreated control group were limited mostly to single cases of irregular, wavy direction of cardiomyocytes (Table 4). Occasionally, a concomitant parenchymatous degeneration and interstitial edema were also revealed. The highest occurrence of pathological changes was found in groups exposed exclusively to doxorubicin (Figure 5). The effect was dose-dependent since massive necrosis was found only in 4 of 6 animals exposed to the high dose of the drug (Figure 6). In the remaining two animals and in 4 out of 6 ones from the group treated with a low dose of doxorubicin, the necrosis was limited to single, spread cardiomyocytes. In all cases an inflammatory infiltration was located around necrotic loci. Dose dependence was also confirmed in case of the eosinophilic degeneration and interstitial edema. A lower incidence but similar histological changes were observed in groups concomitantly treated with doxorubicin and resveratrol (Figure 7). Insignificantly higher occurrence of the eosinophilic degeneration was found in the group cotreated with resveratrol and a low-dose doxorubicin, when compared with rats exposed only to the low dose of the drug, while a lower incidence of such abnormality was revealed in animals exposed to resveratrol and a high dose of doxorubicin. However, the incidence of necrosis and inflammatory infiltration was lower than that in the groups exposed only to doxorubicin.
Hepatic changes were occasionally observed in the control group (Table 5). The parenchymatous (Figure 8) and eosinophilic hepatic degeneration (Figure 9) was the most commonly observed among all the xenobiotic-exposed groups. Usually, they were limited to centri- and midlobular zones. Activation of cells lining to sinus zone was also observed in such cases. Many disseminated eosinophilic hepatocytes presented an intensive cytoplasmic paS reaction (Figure 10). Moreover, d-paS staining performed in the paS-positive cases and in organs with the eosinophilic degeneration showed an extracytoplasmic, intrahepatic capacity, which corresponds to the glycogen accumulation. However, some hepatocytes with the eosinophilic degeneration did not stain in the paS method before and after diastase digestion. The highest but similar occurrence of the parenchymatous and eosinophilic hepatic degeneration was found in two groups treated exclusively with doxorubicin. However, the vacuolar degeneration and pycnotic nuclei of hepatocytes were observed only in rats treated with a high dose of the drug and in groups exposed to both examined xenobiotics. The occurrence of hepatic changes was insignificantly lower among the animals co-treated with doxorubicin and resveratrol. Unlike that in the case of the hearts, lack of necrosis was found in the examined livers but occasionally some local accumulation of mononuclear inflammatory cells, mainly in mid- and centrilobular zone, was seen. In two animals exposed to the high dose of doxorubicin and resveratrol, an increased amount of the fibrous connective tissue around the central vein was found (Figure 11). There were no features of cholestasis or fibrosis in van Gieson’s staining.
As it was expected, DOX in the two tested doses induced oxidative stress in rat heart and liver. The protective effect of resveratrol against lipid peroxidation was only found in the heart of rats exposed to a lower dose of DOX. It is worth to stress that at the same time resveratrol slightly intensified adverse cardiac histological changes in rats receiving a lower dose of DOX, but it also attenuated necrosis and other histopathological changes in the heart induced by a higher dose of the drug. Moreover, resveratrol had no protective influence on the liver oxidative stress and while having a mild beneficial effect on the organ morphological changes caused by doxorubicin.
In this study, DOX was administered 7 times, every next week in the doses 1.0 or 2.0 mg/kg, which according to other studies represents no observed general toxic effect and general toxic effects without mortality, respectively . However, a similar schedule using even 0.8 mg doxorubicin/kg results in adverse cardiac effects on the histological, ultrastructural and biochemical level . According to the current hypotheses referring to prolonged DOX-dependent cardiotoxicity, oxidative damage caused directly by DOX leads to mitochondrial DNA (mtDNA) damage, which in turn is responsible for mitochondrial dysfunction . No changes in mitochondrial electron transfer result in oversynthesis reactive oxygen species . For that reason we assessed the oxidative stress marker (MDA+4HNE) 96 hours after the last seventh dose of the drug, since the intramyocardial half-life of DOX appears to be only a few hours .
In this study resveratrol was taken by the rats in the fodder (20 ppm). Assuming that the average daily amount of fodder taken by rats weighing 100 g is 10 g, the dose of resveratrol is 2.0 mg/kg. It is a very low dose because NOAEL (no observed adverse effect level) for resveratrol estimated in a 28-day test, when rats were administered every day intragastrically, equals 300 mg/kg . Clinically, a well-tolerated dose of resveratrol is up to 5 g/day (approximately 70 mg) . In the studies with resveratrol the usually used doses are within the range of 3 mg/kg−120 mg/kg body weight or 5 g/kg of fodder [47–50].
To evaluate DOX cardiac and hepatic toxicity and to assess the effect of resveratrol on those changes, the markers of oxidative stress, histopathological features, and especially necrosis and blood biochemical parameters, were analyzed. Among the oxidative stress parameters the cardiac and hepatic lipid peroxidation products (MDA+4HNE), GSH/GSSG ratio, total glutathione GSHT and activity of superoxide dismutase were determined. Resveratrol was found to have a significant protective role in the heart, since lipid peroxidation induced by a lower dose of doxorubicin was diminished in the group DOX+1RV to the level seen in the control. Similarly, residual activity of SOD—the key enzyme neutralizing , generated by doxorubicin was lower in cardiac homogenates in group 1DOX+RV than that in 1DOX group. The rational explanation of the SOD phenomena is difficult, especially in the light of a lack of such changes comparing 2DOX+RV with 2DOX. However, the aforementioned protective role of resveratrol referring to lipid peroxidation may be attributed to the ROS scavenging activity of resveratrol which was confirmed by Murias et al.  and Leonard et al. . No sign of the protective effect of resveratrol against the cardiac lipid peroxidation of rats administered with a higher dose of doxorubicin (2DOX versus 2DOX+RV) may result from ROS overproduction, which cannot be composed by resveratrol. According to the study by Kitada et al. , resveratrol can improve the antioxidative potential via reduction of tyrosine-nitrated modification of SOD, but the applied dose was 1500-fold higher than that in this study. The absence of the effect of phytophenol on the oxidative stress in the liver induced by doxorubicin may have a similar background. There is much higher activity of enzymes taking part in one electron reduction of DOX in the liver . Thus, abundance of ROS caused oxidative stress cannot be scavenged by resveratrol. Moreover, resveratrol undergoes intensive metabolism by sulfotransferases and glucuronosyltransferases highly expressed in the liver .
Different effects of resveratrol on cardiac histology were observed. However, it generally depended on the doxorubicin dose. Resveratrol strengthened the morphological adverse changes in the heart of rats given a lower dose of DOX and attenuated the pathological features when the dose of the chemotherapeutic drug was higher. The reasonable explanation of that is that resveratrol in some redox conditions may act as an antioxidative but in other conditions as a prooxidative factor. However, comparing the DOX versus DOX+RV groups, it may be found that changes in the morphological features of the heart are not accompanied by oxidative stress, thus, oxidative stress of the rats administered with DOX and resveratrol plays an important but not a crucial role in morphological changes. It was clearly seen in the groups 2DOX+RV, when MDA+4HNE concentration was the highest among all the tested groups, but necrosis in the heart estimated histopathologically and biochemically (FABP) was significantly reduced. Moreover, the normalizing effect of resveratrol was also found referring to the contractility function. A higher dose of doxorubicin significantly elevated blood BNP level, but resveratrol given together with 2DOX significantly reduced BNP level. On the basis of the current knowledge, it is difficult even to speculate about the reason for that. On the other hand, there were no features of necrosis in the liver, but resveratrol showed a protective effect against other observed morphological changes in that organ.
Furthermore, there were no significant differences in serum activity of LDH, CK, AST, ALT, and ALP between, DOX and DOX+RV group. However, in the group 1DOX+RV, the level of CK, and in the group 2DOX + RV the levels of AST and ALT were lower than control in contrast with DOX groups, where there were no significant differences comparing to the control.
The range of changes in red-ox parameters may differ between the heart and the liver. In the group of 1DOX+RV, significantly higher relative changes in liver MDA+4HNE, GSHT and SOD level comparing to the heart were found. However, there were no such complex changes between the heart and the liver in the other groups. The changes in MDA+4HNE level indicate that oxidative stress is stronger in the liver than in the heart and a higher level of GSHT and SOD may be interpreted as an adaptation feedback on oxidative changes. In conditions of the conducted study, the effect of oxidative/antioxidative changes in the organs is dependent mainly on two mechanisms the first being the efficiency of xenobiotic-dependent ROS overproduction and the second, the potential of antioxidative organ defence. The liver, because of the xenobiotic metabolism, may produce an important amount of ROS but at the same time the activity of antioxidative defence is a few times higher than, for example, that in the heart [56–58]. Probably, the difference between the heart and the liver in the group of 1DOX+ RV results predominantly from the metabolism of doxorubicin and resveratrol by the liver. Both are metabolised by the monooxygenase system (cytochromes P450) which produces ROS [18, 59]. Interestingly, there were no morphological feature of necrosis in the liver contrary to the heart, where necrosis was observed in all the studied groups.
In the light of this study, the questions arise why a higher hepatic oxidative stress comparing to the heart did not cause necrosis and why despite a higher oxidative stress in the liver, the target of long-term toxicity is the heart and not the liver. Moreover, this comparison may indicate that oxidative stress is not a major necrosis predictor. The compartmentalization of the subcellular oxidative stress seems to be reasonable to explain these questions. Although, superoxide radical may freely diffuse through intracellular membranes, subcellular compartmentalization of glutathione may significantly modulate the harmful activity of ROS in subcellular compartments . Therefore, probably more important is not the sum of oxidative stress in all cell organelles, as was measured in this study, but the level of mitochondrial oxidative stress. According to this assumption, a moderately higher level of ROS, for example, in cytoplasm, does not destroy the cell membrane—the key feature of necrosis—but mitochondria ROS overproduction may cause inhibition of the cell membrane pumps resulting from reduced ATP synthesis and triggers the necrosis pathway. That interpretation is also consistent with the obtained results and the current knowledge, according to which the target organ in long-term DOX toxicity is the heart but not the liver.
In conclusion, resveratrol had different effects on the oxidative stress and cardiac morphology, which was generally dependent on the dose of doxorubicin. The phytophenol reduced the incidence of cardiac necrosis in rats treated with a higher dose of doxorubicin. It also had an insignificant effect on the hepatic oxidative stress but the substance normalized the organ morphology. In sum, those results give a hope that future studies with higher doses of resveratrol can improve doxorubicin related-toxicity to a broader extent. Due to the number of differences between humans and laboratory rats, the obtained result cannot be directly applied in the human clinical practice. For this reason, more intensive studies, including other nonrodent species, are necessary.
Conflict of Interests
The authors declare that there is no conflict of interests.
- J. M. Fulbright, “Review of cardiotoxicity in pediatric cancer patients: during and after therapy,” Cardiology Research and Practice, vol. 2011, Article ID 942090, 9 pages, 2011.
- M. Feola, O. Garrone, M. Occelli et al., “Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin i and brain natriuretic peptide,” International Journal of Cardiology, vol. 148, no. 2, pp. 194–198, 2011.
- J. Dudka, F. Burdan, A. Korga et al., “The diagnosis of anthracycline-induced cardiac damage and heart failure,” Postępy Higieny i Medycyny Doświadczalnej, vol. 63, pp. 225–233, 2009.
- M. A. Grenier and S. E. Lipshultz, “Epidemiology of anthracycline cardiotoxicity in children and adults,” Seminars in Oncology, vol. 25, no. 4, pp. 72–85, 1998.
- L. J. Steinherz, P. G. Steinherz, C. T. C. Tan, G. Heller, and M. L. Murphy, “Cardiac toxicity 4 to 20 years after completing anthracycline therapy,” Journal of the American Medical Association, vol. 266, no. 12, pp. 1672–1677, 1991.
- G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004.
- A. Korga, J. Dudka, F. Burdan, J. Sliwinska, S. Mandziuk, and K. Daniwdek-Pietryka, “The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and doxorubicin,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 681367, 9 pages, 2012.
- M. F. Xu, P. L. Tang, Z. M. Qian, and M. Ashraf, “Effects by doxorubicin on the myocardium are mediated by oxygen free radicals,” Life Sciences, vol. 68, no. 8, pp. 889–901, 2001.
- J. H. Doroshow, “Effect of anthracycline antibiotics on oxygen radical formation in rat heart,” Cancer Research, vol. 43, no. 2, pp. 460–472, 1983.
- N. R. Bachur, S. L. Gordon, and M. V. Gee, “A general mechanism for microsomal activation of quinone anticancer agents to free radicals,” Cancer Research, vol. 38, no. 6, pp. 1745–1750, 1978.
- J. Vásquez-Vivar, P. Martasek, N. Hogg, B. S. S. Masters, K. A. Pritchard, and B. Kalyanaraman, “Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin,” Biochemistry, vol. 36, no. 38, pp. 11293–11297, 1997.
- M. A. Mansour, A. G. El-Din, M. N. Nagi, O. A. Al-Shabanah, and A. M. Al-Bekairi, “Nω-nitro-L-arginine methylester ameliorates myocardial toxicity induced by doxorubicin,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 6, pp. 593–596, 2003.
- R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair, and T. D. Oberley, “Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?” Antioxidants and Redox Signaling, vol. 9, no. 7, pp. 1001–1008, 2007.
- Y. Zhao, D. McLaughlin, E. Robinson et al., “Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy,” Cancer Research, vol. 70, no. 22, pp. 9287–9297, 2010.
- S. Deng, A. Kruger, A. L. Kleschyov, L. Kalinowski, A. Daiber, and L. Wojnowski, “Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH,” Free Radical Biology and Medicine, vol. 42, no. 4, pp. 466–473, 2007.
- S. B. Yee and C. A. Pritsos, “Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase,” Archives of Biochemistry and Biophysics, vol. 347, no. 2, pp. 235–241, 1997.
- J. Dudka, “The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity,” Postępy Higieny i Medycyny Doświadczalnej, vol. 60, pp. 241–247, 2006.
- A. E. Crib, M. Peyrou, S. Muruganandan, and L. Schneider, “The endoplasmic reticulum in xenobiotic toxicity,” Drug Metabolism Reviews, vol. 37, no. 3, pp. 405–442, 2005.
- J. M. Berthiaume and K. B. Wallace, “Adriamycin-induced oxidative mitochondrial cardiotoxicity,” Cell Biology and Toxicology, vol. 23, no. 1, pp. 15–25, 2007.
- V. A. Sardão, P. J. Oliveira, J. Holy, C. R. Oliveira, and K. B. Wallace, “Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets,” Cell Biology and Toxicology, vol. 25, no. 3, pp. 227–243, 2009.
- U. A. Boelsterli, Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Target, Taylor & Francis, New York, NY, USA, 2003.
- S. Zhou, C. M. Palmeira, and K. B. Wallace, “Doxorubicin-induced persistent oxidative stress to cardiac myocytes,” Toxicology Letters, vol. 121, no. 3, pp. 151–157, 2001.
- J. M. Berthiaume and K. B. Wallace, “Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment,” Cardiovascular Toxicology, vol. 7, no. 3, pp. 178–191, 2007.
- O. A. Al-Shabanah, A. M. Aleisa, M. M. Hafez, and ETAL, “Desferroxamine attenuates doxorubicin induced acute cardiotoxicity through TGF-β/Smad p53 pathway in rat model,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 213112, 7 pages, 2012.
- Y. W. Zhang, J. Shi, Y. J. Li, and L. Wei, “Cardiomyocyte death in doxorubicin-induced cardiotoxicity,” Archivum Immunologiae et Therapia Experimentalis, vol. 57, pp. 435–445, 2009.
- K. L. Thompson, B. A. Rosenzweig, J. Zhang et al., “Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 303–314, 2010.
- A. V. Pointon, T. M. Walker, K. M. Phillips et al., “Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation,” PLoS ONE, vol. 5, no. 9, p. e12733, 2010.
- K. R. Patel, E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown, “Clinical trials of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, pp. 161–169, 2011.
- J. M. Smoliga, J. A. Baur, and H. A. Hausenblas, “Resveratrol and health—a comprehensive review of human clinical trials,” Molecular Nutrition and Food Research, vol. 55, no. 8, pp. 1129–1141, 2011.
- B. B. Aggarwal, A. Bhardwaj, R. S. Aggarwal, N. P. Seeram, S. Shishodia, and Y. Takada, “Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies,” Anticancer Research, vol. 24, no. 5, pp. 2783–2840, 2004.
- Y. A. Rezk, S. S. Balulad, R. S. Keller, and J. A. Bennett, “Use of Resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart,” American Journal of Obstetrics and Gynecology, vol. 194, no. 5, pp. e23–e26, 2006.
- A. M. Al-Abd, A. M. Mahmoud, G. A. El-Sherbiny, et al., “Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro,” Cell Proliferation, vol. 44, pp. 591–601, 2011.
- M. Sato, N. Maulik, and D. K. Das, “Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants,” Annals of the New York Academy of Sciences, vol. 957, pp. 122–135, 2002.
- S. Das, M. Falchi, A. Bertelli, N. Maulik, and D. K. Das, “Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol,” Arzneimittel-Forschung/Drug Research, vol. 56, no. 10, pp. 700–706, 2006.
- D. J. Luther, V. Ohanyan, P. E. Shamhart et al., “Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma,” Investigational New Drugs, vol. 29, no. 2, pp. 380–391, 2011.
- S. Roy, S. Sannigrahi, S. Majumdar, B. Ghosh, and B. Sarkar, “Resveratrol regulates antioxidant status, inhibits cytokine expression and restricts apoptosis in carbon tetrachloride induced rat hepatic injury,” Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 703676, 2011.
- A. Kumar, C. K. Singh, H. A. Lavoie, D. J. Dipette, and U. S. Singh, “Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders,” Molecular Pharmacology, vol. 80, pp. 446–457, 2011.
- Z. Ungvari, Z. Bagi, A. Feher et al., “Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2,” American Journal of Physiology, vol. 299, no. 1, pp. H18–H24, 2010.
- G. Haskó and P. Pacher, “Endothelial Nrf2 activation: a new target for resveratrol?” American Journal of Physiology, vol. 299, no. 1, pp. H10–H12, 2010.
- Z. Cao and Y. Li, “Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury,” European Journal of Pharmacology, vol. 489, no. 1-2, pp. 39–48, 2004.
- E. D. Brookins Danz, J. Skramsted, N. Henry, J. A. Bennett, and R. S. Keller, “Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway,” Free Radical Biology and Medicine, vol. 46, no. 12, pp. 1589–1597, 2009.
- J. Szumilo, Wpływ Resweratrolu i Kwasu Protokatecholowego na Rozwój Nowotworów Płaskonabłonkowych Przełyku u Szczura Indukowanych Przez N-Nitrozometylobenzyloaminę, Poland Medical University of Lublin, Lublin, Poland, 2007.
- J. A. Crowell, P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine, “Resveratrol-associated renal toxicity,” Toxicological Sciences, vol. 82, no. 2, pp. 614–619, 2004.
- D. Lebrecht, A. Geist, U. P. Ketelsen, J. Haberstroh, B. Setzer, and U. A. Walker, “Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats,” British Journal of Pharmacology, vol. 151, no. 6, pp. 771–778, 2007.
- J. J. Lemasters and A. L. Nieminen, Mitochondria in pathogenesis, Academic/Plenum, New York, NY, USA, 2001.
- B. A. Johnson, M. S. Cheang, and G. J. Goldenberg, “Comparison of adriamycin uptake in chick embryo heart and liver cells and murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity,” Cancer Research, vol. 46, no. 1, pp. 218–223, 1986.
- G. Y. Wang, Y. M. Wang, L. N. Zhang et al., “Effect of resveratrol on heart function of rats with adriamycin-induced heart failure,” Zhongguo Zhongyao Zazhi, vol. 32, no. 15, pp. 1563–1565, 2007.
- A. Kasdallah-Grissa, B. Mornagui, E. Aouani et al., “Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver,” Life Sciences, vol. 80, no. 11, pp. 1033–1039, 2007.
- P. Vitaglione, B. Ottanelli, S. Milani, F. Morisco, N. Caporaso, and V. Fogliano, “Dietary trans-resveratrol bioavailability and effect on CCl 4-induced liver lipid peroxidation,” Journal of Gastroenterology and Hepatology, vol. 24, no. 4, pp. 618–622, 2009.
- G. Şener, N. Topaloǧlu, A. Özer Şehirli, F. Ercan, and N. Gedik, “Resveratrol alleviates bleomycin-induced lung injury in rats,” Pulmonary Pharmacology and Therapeutics, vol. 20, no. 6, pp. 642–649, 2007.
- M. Murias, W. Jäger, N. Handler et al., “Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship,” Biochemical Pharmacology, vol. 69, no. 6, pp. 903–912, 2005.
- S. S. Leonard, C. Xia, B. H. Jiang et al., “Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses,” Biochemical and Biophysical Research Communications, vol. 309, no. 4, pp. 1017–1026, 2003.
- M. Kitada, S. Kume, N. Imaizumi, and D. Koya, “Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1—independent pathway,” Diabetes, vol. 60, no. 2, pp. 634–643, 2011.
- J. Dudka, J. Jodynis-Liebert, E. Korobowicz et al., “Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study,” Basic and Clinical Pharmacology and Toxicology, vol. 97, no. 2, pp. 74–79, 2005.
- A. Maier-Salamon, M. Böhmdorfer, T. Thalhammer, T. Szekeres, and W. Jaeger, “Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog,” Drug Metabolism and Pharmacokinetics, vol. 26, pp. 364–373, 2011.
- R. D. Olson and P. S. Mushlin, “Doxorubicin cardiotoxicity: analysis of prevailing hypotheses,” FASEB Journal, vol. 4, no. 13, pp. 3076–3086, 1990.
- Y. Chen, J. T. Saari, and Y. J. Kang, “Weak antioxidant defenses make the heart a target for damage in copper-deficient rats,” Free Radical Biology and Medicine, vol. 17, no. 6, pp. 529–536, 1994.
- R. H. M. Julicher, L. Sterrenberg, G. R. M. M. Haenen, A. Bast, and J. Noordhoek, “The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat,” Archives of Toxicology, vol. 61, no. 4, pp. 275–281, 1988.
- B. Piver, M. Fer, X. Vitrac et al., “Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes,” Biochemical Pharmacology, vol. 68, no. 4, pp. 773–782, 2004.
- R. M. Green, M. Graham, M. R. O'Donovan, J. K. Chipman, and N. J. Hodges, “Subcellular compartmentalization of glutathione: correlations with parameters of oxidative stress related to genotoxicity,” Mutagenesis, vol. 21, no. 6, pp. 383–390, 2006.